Business Wire

ExOne Opens State-of-the-Art Metal 3D Printing Adoption Center in Europe, Expands Engineering Support

Share

The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today announced it has opened a Metal 3D Printing Adoption Center at its European headquarters in Gersthofen, Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210708005298/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Eric Bader, Managing Director of ExOne GmbH, says the launch of ExOne's Metal 3D Printing Adoption Center is driven by increased interest by European manufacturers in metal binder jet 3D printing. ExOne’s Adoption Centers now print sand molds and cores for metalcasting customers, as well as metal benchmarks for its metal binder jetting engineering consulting services. (Photo: Business Wire)

The mission of ExOne’s Adoption Centers, which have locations in the U.S., Germany, and Japan, is to allow customers to try binder jet 3D printing for their designs before they decide to buy an ExOne 3D printing system for their own production.

The investment announced today represents an expansion of ExOne’s longtime Adoption Center in Europe, which 3D prints sand molds and cores for metalcasting customers. ExOne’s Metal Adoption Center now offers manufacturers end-to-end engineering services for direct-metal binder jet 3D printing, including benchmarks, design support, and materials, process, and work cell development.

“Now, manufacturers throughout Europe can benefit from locally produced binder jetted metal designs and benchmarks, along with world-class engineering consultation and support,” said John Hartner, ExOne’s CEO. “We encourage manufacturers to take advantage of the high speed, low cost, and industry-leading quality that our patented binder jetting technology can deliver for even the most complex designs.”

“Our centralized location outside of Munich gives manufacturers the opportunity to see metal binder jetting in action and work closely with our expanded metal team on precision metal parts projects,” said Eric Bader, Managing Director, ExOne GmbH. “This expansion is supported by increased interest in metal binder jetting in Europe as the technology matures.”

High-Quality Metal Parts Key Focus of New Center

Binder jetting is a high-speed method of 3D printing in which an industrial inkjet printhead selectively deposits a binder into a bed of powder particles creating a solid part one thin layer at a time. When printing metals, the final part must be sintered in a furnace to fuse the particles together into a high-density solid object.

All new ExOne metal printers, such as the X1 160Pro manufactured on-site in Gersthofen, are now offered with the company’s patented Triple Advanced Compaction Technology (ACT), which delivers industry-leading accuracy, density, and repeatability in binder jet printing.

ExOne has now qualified more than 20 metal, ceramic, and composite materials for its binder jetting process. More than half of those materials are single-alloy metals, such as 17-4PH, 316L, 304L, M2 Tool Steel, Inconel 718, and more. Most recently, ExOne announced that 6061 aluminum is now a Customer-Qualified material, and titanium is now fast-tracked for qualification in partnership with a global medical device firm.

ExOne’s New Metal 3D Printing Adoption Center will initially focus on the delivery of small-to-medium parts with quality similar to Metal Injection Molding (MIM) in 316L and 17-4PH, with other materials available. To exploring having your part or product metal 3D printed with ExOne technology, contact ExOne through exone.com/EMEAmetal or +49 821 65063 238.

About ExOne

ExOne is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sarah Webster
724.516.2336
sarah.webster@exone.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM and Scientek Corporation Sign Reseller Agreement to Boost Quantum Computing in Taiwan18.9.2025 11:11:00 EEST | Press release

IQM Quantum Computers and Scientek Corporation, a Taiwan-based reseller of scientific instruments and other high-technology products, today announced the signing of a strategic reseller agreement to accelerate the commercialisation of quantum computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918110284/en/ IQM and Scientek Corporation sign reseller agreement The agreement follows the installation of IQM Spark, the first full-stack superconducting quantum computer at the Taiwan Semiconductor Research Institute (TSRI). Under the reseller agreement, Scientek will sell and promote IQM’s on-premises quantum computers and cloud solutions that meet the evolving needs of universities, research institutions, and enterprises. Combining Scientek's strong market presence and customer-centric approach in Taiwan with IQM’s quantum leadership, the collaboration will help Taiwanese businesses and research institutions to explore a

Acuity Knowledge Partners Acquires Ascent18.9.2025 10:30:00 EEST | Press release

Acuity Knowledge Partners (Acuity), a leading global provider of bespoke research, data management, analytics and AI solutions to the financial services sector, has announced that it has exchanged on the acquisition of Ascent. The transaction is expected to close on 30th September 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915732380/en/ L-R: Stewart Smythe, Chief Executive Officer, Ascent; Jon O'Donnell, Chief Operating Officer, Acuity Knowledge Partners, and Robert King, Chief Executive Officer, Acuity Knowledge Partners This strategic move significantly expands Acuity's Data and Technology Services (DTS) division and its offering of technology and AI led services and solutions. Ascent, a leading European provider of AI-powered digital transformation services, supports over 170 clients globally, with 550 data, software, and cloud specialists operating across seven European jurisdictions. “Our acquisition of Asc

Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 202518.9.2025 09:00:00 EEST | Press release

Almirall, S.A. (ALM) a global biopharmaceutical company focused on medical dermatology today announced new long-term results from the POSITIVE study, presented as a late-breaker at the 34th Congress of the European Academy of Dermatology and Venereology 2025 (EADV) in Paris. POSITIVE is the first RWE study in dermatology to use the World Health Organization Well-Being Index (WHO-5) as a primary endpoint. The selection of the abstract as a late breaker at the EADV congress highlights the importance of the findings of the POSITIVE study and its unique approach to evaluating the long-term holistic impact of an advanced treatment in patients with moderate-to-severe psoriasis, a condition that profoundly impairs social, psychological, and physical quality of life, impacting overall well-being1. Two‑Year Real‑World Results from POSITIVE The 24-month, multinational, phase IV observational study enrolled 785 adult patients with moderate-to-severe plaque psoriasis across nine European countries

Shield and PwC UK Forge Strategic Collaboration to Deliver Future-Ready Communications Compliance18.9.2025 09:00:00 EEST | Press release

Shield, a leading AI platform for digital communication governance and archiving, today announced a collaboration with PwC UK, one of the world’s most trusted professional services firms. The alliance brings together Shield’s unified, cloud-native solution with PwC’s specialist expertise in communications surveillance delivery, regulatory compliance and complex programme execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917394739/en/ Shield and PwC launch a strategic collaboration to modernize eComms surveillance with AI-driven compliance solutions for financial institutions. The collaboration is designed to support institutions as they modernise their approach to communications monitoring, helping them implement an advanced and proactive risk management approach at scale and with confidence. This joint offering provides an end-to-end solution designed to meet evolving regulatory expectations, accelerate adoption

Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 318.9.2025 08:00:00 EEST | Press release

Curatis Holding AG (SIX:CURN) received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye